AI Tool Predicts Deadly Brain Swelling After Stroke

Doctors now have a powerful new ally in the race against time after a major stroke.

BEACONPredict, an AI software tool developed by researchers at Washington University in St. Louis, can predict which stroke patients are at risk for malignant cerebral edema. That's the medical term for dangerous brain swelling that can turn deadly within hours.

The tool reads early brain scans alongside clinical information and gives doctors a clear risk score. Armed with that knowledge, medical teams can ramp up monitoring or perform life-saving surgery before a patient deteriorates beyond help.

Dr. Raj Dhar, a neurology professor at WashU Medicine, built the science behind BEACONPredict in his neurocritical care lab. But moving from lab research to a tool doctors can actually use meant navigating the FDA approval process, something research labs aren't equipped to handle.

That's where Innolitics stepped in. The medical device software company partnered with Dr. Dhar's startup, BEACON-Neuro.AI, to transform the prototype into something the FDA would accept. The collaboration worked. BEACONPredict received FDA Breakthrough Device Designation on its very first review cycle, a rare achievement that signals both innovation and urgent medical need.

Dr. Yujan Shrestha, a partner at Innolitics, credits the success to seamless teamwork. "That happens when the clinical team and the regulatory team are working off one plan instead of passing documents back and forth," he said.

The FDA designation also brought BEACONPredict into a pilot program that provides enhanced FDA support and could speed up insurance reimbursement after final approval. The tool is now working through the De Novo pathway, a regulatory route for novel low-to-moderate risk devices.

Why This Inspires

Predicting malignant cerebral edema is one of the toughest calls in emergency neurology. It strikes after large strokes, and the window to act is terrifyingly narrow. For years, doctors have relied on experience and intuition to spot the warning signs. Now they'll have data-driven support at exactly the moment it matters most.

BEACON-Neuro.AI is raising funds to bring the tool through final FDA clearance and into hospitals. While the device isn't yet approved for commercial use, the progress represents something bigger: artificial intelligence stepping up where human medicine faces its hardest challenges, not to replace doctors but to help them make better decisions faster.

Thousands of stroke patients face this complication every year, and earlier detection means more families get second chances.

#